Voxvoganan trihydrochloride
(Synonyms: LTX-109 trihydrochloride) 目录号 : GC70127Voxvoganan (LTX-109) trihydrochloride 是一种局部抗菌剂 (antimicrobial)，对 S. aureus 非常有效，MIC为2-4 μg/mL。Voxvoganan trihydrochloride 可用于细菌性皮肤感染、真菌感染的研究。
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Voxvoganan (LTX-109) tridrochloride, a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan tridrochloride can be used for the research of fungal infections and nasal decolonisation of MRSA[1][2].
Voxvoganan tridrochloride (LTX-109) is an investigational antimicrobial agent with a membrane-lysing mechanism of action, based on the biological principle of innate immune effectors, lytic peptides. Voxvoganan tridrochloride has a rapid bactericidal lytic activity. Voxvoganan tridrochloride demonstrates in vitro bactericidal activity against a number of S. aureus isolates resistant to several classes of antimicrobial agents evaluated in this study[2].
Voxvoganan tridrochloride (LTX-109) is a broad-spectrum, fast-acting bactericidal antimicrobial agent that binds to negatively charged membrane components on the bacterial cell wall, which leads to membrane disruption and cell lysis. Voxvoganan tridrochloride is a first-in-class chemically synthesized, small peptide drug that is stable against protease degradation. Topical application of Voxvoganan tridrochloride has a good safety profile and a low bioavailability. Voxvoganan tridrochloride demonstrates good activity against Staplococcus aureus strains that are susceptible and resistant to mupirocin[3].
[1]. Johan Isaksson, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
[2]. Louis D Saravolatz, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staplococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82.
[3]. L D Saravolatz, et al. Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staplococcus aureus blood isolates. Lett Appl Microbiol. 2017 Nov;65(5):410-413.
| Cas No. | SDF | Download SDF | |
| 别名 | LTX-109 trihydrochloride | ||
| 分子式 | C43H72Cl3N11O3 | 分子量 | 897.46 |
| 溶解度 | DMSO : 140 mg/mL (156.00 mM; Need ultrasonic) | 储存条件 | 4°C, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1143 mL | 5.5713 mL | 11.1426 mL |
| 5 mM | 222.9 μL | 1.1143 mL | 2.2285 mL |
| 10 mM | 111.4 μL | 557.1 μL | 1.1143 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet